Opinion|Videos|July 24, 2024
Future Implications of Combination Regimens and Treatment Duration in CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are the future implications of fixed-duration therapy for patients with CLL/SLL?
- What are the implications of the SEQUOIA Arm D and CAPTIVATE studies for this therapeutic approach?
- What are the implications of the SEQUOIA Arm D and CAPTIVATE studies for this therapeutic approach?
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5